~~<i id='21174CEC41'><strike id='21174CEC41'><tt id='21174CEC41'><pre id='21174CEC41'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：explore 2025-10-04 06:03:22 Page View：137

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Van's Gluten Free Original Waffles recalled for possible wheat allergen
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Custom gene therapy hints at new path for rare disease treatments

AdobeWhenTimothyYudevelopedmilasen,acustomdrugforayounggirlnamedMilawithBattendisease,heignitedaspar

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Sanders adds drug shortage policies to pandemic preparedness bill

Sen.BernieSanders(I-Vt.)addedthreedrugshortagemeasurestoapandemic-preparednessbillthathiscommitteewi